SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology | bioRxiv https://www.biorxiv.org/content/10.1101/2022.01.31.478476v3



Search

#### New Results

## **Follow this preprint** O Previous

## SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology

Wei-Bin Shen, Montasir Elahi, James Logue, Penghua Yang, Lauren Baracco, E. Albert Reece, Bingbing Wang, Ling Li, 🔽 Print/Sav Thomas G Blanchard, 💿 Zhe Han, 💿 Robert A Rissman, Matthew B Frieman, Peixin Yang 📝 Revision doi: https://doi.org/10.1101/2022.01.31.478476

This article is a preprint and has not been certified by peer review [what does this mean?].

	🚰 3 😂 0	38 🖽 0	10890		
Abstract	Full Text	Info/History	Metrics	Preview PDF	X Post

### Abstract

The neurotropism of SARS-CoV-2 and the phenotypes of infected neurons are still in debate. Long COVID manifests with "brain diseases" and the cause of these brain dysfunction is mysterious. Here, we analyze 34 age- and underlying disease-matched COVID-19 or non-COVID-19 human brains. SARS-CoV-2 RNA, nucleocapsid, and spike proteins are present in neurons of the cognitive centers of all COVID-19 patients, with its non-structural protein NSF2 detected in adult cases but not in the infant case, indicating viral replications in mature neurons. In adult COVID-19 patients without underlying neurodegeneration, SARS-CoV-2 infection triggers Aβ and p-tau deposition, degenerating neurons, microglia activation, and increased cytokine, in some cases with Aβ plaques and p-tau pretangles. The number of SARS-CoV-2<sup>+</sup> cells is higher in patients with neurodegenerative diseases than in those without such conditions. SARS-CoV-2 further activates microglia and induces AB and p-tau deposits in non-Alzheimer's neurodegenerative disease patients. SARS-CoV-2 infects mature neurons derived from inducible pluripotent stem cells from healthy and Alzheimer's disease (AD) individuals through its receptor ACE2 and facilitator neuropilin-1. SARS-CoV-2 triggers AD-like gene programs in healthy neurons and exacerbates AD neuropathology. An AD infectious etiology gene signature is identified through SARS-CoV-2 infection and silencing the top three downregulated genes in human primary neurons recapitulates the neurodegenerative phenotypes of SARS-CoV-2. Thus, our data suggest that SARS-CoV-2 invades the brain and activates an AD-like program.

### Competing Interest Statement

The authors have declared no competing interest.

Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.All rights reserved. No reuse allowed without permission.

### bioRxiv and medRxiv thank the following for their generous financial support:

The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.

∧ Back to top

\*The Clini



ad PDF	🖂 Email
ave Options	Anare Share
Summary	Citation Tools
	🍨 Audio abstract
	Get QR code

## 📫 Like 27

# COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

## Subject Area

Neuroscience

### Subject Areas

### **All Articles**

Animal Behavior and Cognition				
Biochemistry				
Bioengineering				
Bioinformatics				
Biophysics				
Cancer Biology				
Cell Biology				
Clinical Trials*				
Developmental Biology				
Ecology				
Epidemiology*				
Evolutionary Biology				
Genetics				
Genomics				
Immunology				
Microbiology				
Molecular Biology				
Neuroscience				
Paleontology				
Pathology				
Pharmacology and Toxicology				
Physiology				
Plant Biology				
Scientific Communication and Education				
Synthetic Biology				
Systems Biology				
Zoology				
ical Trials and Epidemiology subject categories are now closed to new				

submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).